{"id":"W2293077587","doi":"10.1016/s0140-6736(16)00559-6","title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":638,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; American College of Radiology Imaging Network","keywords":"Sunitinib; Sorafenib; Medicine; Renal cell carcinoma; Placebo; Oncology; Internal medicine; Adjuvant; Clinical endpoint; Clinical trial; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002145394,0.0006272065,0.002619864,0.0002002218,0.0002801515,0.0000770357,0.0004976616,0.0001356846,0.0007047149],"category_scores_gemma":[0.0005693506,0.0002764552,0.0006631493,0.0002394677,0.0002009128,0.0001279371,0.00009083941,0.0003513502,0.0002738134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002112883,"about_ca_system_score_gemma":0.00046365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002633696,"about_ca_topic_score_gemma":0.0001293317,"domain_scores_codex":[0.9961059,0.0004798439,0.001100192,0.0006941905,0.0005795323,0.001040304],"domain_scores_gemma":[0.9941736,0.003057143,0.0006818139,0.001491533,0.0002309045,0.0003650006],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9723392,0.001021017,0.00007770782,0.0001750253,0.0005955223,0.0003253133,0.0003318572,0.00000565559,0.007015209,0.00006252123,0.0114702,0.006580815],"study_design_scores_gemma":[0.9415659,0.007499346,0.0001006294,0.0001515478,0.002725221,0.0001113006,0.0001384414,0.0001468077,0.0431849,0.0002362704,0.00375593,0.0003836697],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748401,0.0005323004,0.001495549,0.003687245,0.0006249106,0.01608906,0.0004735331,0.0001214297,0.002135853],"genre_scores_gemma":[0.9790785,0.0002016274,0.001433043,0.0004061429,0.002975488,0.005186258,0.0001437738,0.0001207476,0.01045444],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03616969,"threshold_uncertainty_score":0.9999688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07669057324285966,"score_gpt":0.3304014740191872,"score_spread":0.2537109007763276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}